| | Dr. Noel Barrett is Vice-President, Vaccines Research in the Bioscience Division of Baxter Healthcare. He received his B. Sc. in Microbiology at University College Cork, Ireland (1976) and his Ph. D. in Virology at Trinity College, Dublin (1979). He subsequently held a post-doctoral fellowship at the Dept. of Virology and Immunology, University of Würzburg, Germany for a period of four years. In 1983, he joined the Austrian company Immuno AG, which was subsequently acquired by Baxter Healthcare in 1997. |
| | Dr. Barrett has been responsible for a variety of functions in the Vaccine business unit including discovery research, clinical development, regulatory affairs and project management, in addition to being responsible for the pathogen safety program of the plasma division for a period of over ten years. He is currently a member of the Baxter AG, Austria board of directors, the Baxter International Senior Management Team and is site manager of the Biomedical Research Centre in Orth. Dr. Barrett has had over twenty years experience in the vaccine industry with management responsibilities covering the complete development process required to bring vaccine products to the market. |
| 1983-1984 | Postdoctoral Fellow, Syntex Inc., Palo alto, CA |
| 1984-1986 | Postdoctoral Fellow, Harvard University, Cambridge, MA |
| 1986-1990 | Scientist, Genentech Inc. |
| 1990-1997 | Vice President of Research, Gilead |
| 1997-2000 | Vice President of Research & Development, Gilead |
| since 2000 | Executive Vice President of Research & Development, Gilead Sciences, Inc. |
| | Studies of Physics and Mathematics at the Universities of Frankfurt and Regensburg |
| 1975 | Dr. rer. Nat. Theoretical Physics, University of Regensburg |
| 1982 | Habilitation Theoretical Physics, University of Regensburg |
| 1988-1989 | Professor of Theoretical Physics, University of Würzburg |
| 1989-1996 | Professor of Theoretical Physics, University of Frankfurt |
| since 1996 | Professor of Theoretical Physics, University of Göttingen |
| Director, Max Planck Institute for Dynamics and Self-Organization |
| | Director, Institute for Nonlinear Dynamics, University of Göttingen |
| | Head, Bernstein Center für Computational Neuroscience, Göttingen |
| 1984-1987 | Research Fellow, Department of Public Veterinary Medicine, Faculty of Veterinary Medicine, University of Leipzig |
| 1987-1989 | Scientist, Institute for Epidemiology and Communicable Disease Control, Federal Research Institute Wusterhausen/Tübingen |
| 1989-1991 | Head, Division of Infectious Diseases, Institute for Epidemiology and Communicable Disease Control, Federal Research Institute Wusterhausen/Tübingen |
| 1992-1993 | Associated Professional Officer (P2); WHO Division of Communicable Diseases, Veterinary Public Health Unit, Geneva |
| 1994-1995 | Scientist (P5); WHO Division of Communicable Diseases, Veterinary Public Health Unit |
| 1995-1998 | Scientist (P5); WHO Division for Emerging and other Communicable Diseases Surveillance and Control |
| 1998-2001 | Senior Scientist (P5); WHO Department of Communicable Diseases Surveillance and Response |
| 2001-2004 | Project Leader (P5); WHO Global Influenza Programme; WHO Department of Communicable Diseases Surveillance and Response |
| 2003 | Coordinator (P5); SARS Aetiology, Diagnosis and Treatment, WHO Department of Communicable Diseases Surveillance and Response |
| 2004-2006 | Coordinator (P5); WHO Global Influenza Programme WHO Department of Communicable Diseases Surveillance and Response |
| since 2006 | Senior Advisor on Influenza Pandemic Vaccine Development, WHO Initiative for Vaccine Research, Department for Immunization, Vaccines and Biologicals |
| 1976-1985 | Medizinstudium, Universität Wien, Abschluss mit Doktorat; außerdem Studien in Geschichte und Ethnologie |
| 1990-1991 | Postgraduate Economics, European Business School, Eltville, Deutschland |
| 1985-1986 | Internship, Medical University of Otago, Dunedin, New Zealand |
| 1986-1987 | Internship, Children's Hospital Oakland, California, USA |
| 1987-1990 | Pharma-Produktmanager, Hoechst Austria AG |
| 1990-1991 | Produktmanager Herz-Kreislauf, Pharma Sales International, Hoechst AG, Frankfurt |
| 1991-1992 | Leiter Pharma, Nigerian Hoechst PLC |
| 1992-1993 | Stv. Geschäftsführer, Leiter Pharma, verantwortlich für Pharma-, Landwirtschafts- und Veterinärprodukte, |
| | Nigerian Hoechst PLC |
| 1993-1994 | Corporate Center, Projektarbeit Afrika, Hoechst AG, Frankfurt |
| 1994-1995 | Assistent von Dr. Seifert, Vorstandsmitglied der Hoechst AG, Frankfurt |
| 1995-1998 | Managing Director, verantwortlich für Pharma-, Diagnostika- und Veterinärprodukte in der Volksrepublik China, |
| | Hongkong und Taiwan, Hoechst Marion Roussel |
| 1998-2000 | Geschäftsführer, Österreich/Central Europe, Hoechst Marion Roussel |
| 2000-2001 | Geschäftsführer, Aventis Pharma GmbH |
| 2001-2004 | Head of Area, Austria & Switzerland, Aventis Pharma GmbH |
| 2004-2008 | General Manager, sanofi-aventis Österreich, Wien |
| 2004-2010 | Präsident, Verband der pharmazeutischen Industrie Österreichs, Wien |
| seit 2010 | Geschäftsführer, Ze.Wa. medicalsystems GmbH, Wien |
